AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please cancel claims 1-8 and 10, and add new claims 14-18, as follows:

1-8.   (Cancelled).

9.   (Original).   A method for prophylaxis of migraine which comprises administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors to a patient.

10.   (Cancelled).

11.   (Previously presented). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors comprises:

a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and

b) a 5-HT_7 receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT_7 receptor.

12.   (Previously presented).   The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors comprises a dual antagonistic compound for the 5-HT_{2B} and 5-HT_7 receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT_7 receptors.

13. (Currently Amended). The method of claim 9, wherein the ~~binding affinity~~ Ki or IC$_{50}$ values for the 5-HT$_{2B}$ and 5-HT$_7$ receptors [[is]]are respectively one-hundredth or ~~more to the~~ less of those of each of α$_1$, M$_1$, D$_2$, 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, 5-HT$_{2C}$, 5-HT$_3$, 5-HT$_4$ and 5-HT$_6$ receptors.

14. (New). The method of claim 9, wherein the binding affinities for the 5-HT2$_B$ and 5-HT$_7$ receptors are higher than those of each of α$_1$, M$_1$, D$_2$, 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_3$, 5-HT$_4$ and 5-HT$_6$ receptors.

15. (New). The method of claim 9, wherein the binding affinities for the 5-HT2$_B$ and 5-HT$_7$ receptors are higher than those of each of α$_1$, M$_1$, D$_2$, 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, 5-HT$_{2C}$, 5-HT$_3$, 5-HT$_4$ and 5-HT$_6$ receptors.

16. (New). The method of claim 9, wherein the Ki or IC$_{50}$ values for the 5-HT2$_B$ and 5-HT$_7$ receptors are respectively one-tenth or less of those of each of α$_1$, M$_1$, D$_2$, 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_3$, 5-HT$_4$ and 5-HT$_6$ receptors.

17. (New). The method of claim 9, wherein the Ki or IC$_{50}$ values for the 5-HT2$_B$ and 5-HT$_7$ receptors are respectively one-tenth or less of those of each of α$_1$, M$_1$, D$_2$, 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, 5-HT$_{2C}$, 5-HT$_3$, 5-HT$_4$ and 5-HT$_6$ receptors.

18. (New). The method of claim 9, wherein the Ki or IC_{50} values for the $5\text{-}HT_{2B}$ and $5\text{-}HT_7$ receptors are respectively one-hundredth or less of those of each of α_1, M_1, D_2, $5\text{-}HT_{1A}$, $5\text{-}HT_{1B}$, $5\text{-}HT_3$, $5\text{-}HT_4$ and $5\text{-}HT_6$ receptors.